Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy

L Musset; P Ghillani; F Lunel; P Cacoub; P Cresta; L Frangeul; M Rosenheim; J L Preud'homme

doi:10.1016/s0165-2478(96)02681-8

Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy

Immunol Lett. 1997 Jan;55(1):41-5. doi: 10.1016/s0165-2478(96)02681-8.

Authors

L Musset¹, P Ghillani, F Lunel, P Cacoub, P Cresta, L Frangeul, M Rosenheim, J L Preud'homme

Affiliation

¹ Laboratory of Immunochemistry, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

PMID: 9093880
DOI: 10.1016/s0165-2478(96)02681-8

Abstract

Serum IgG1 levels are selectively increased in patients with chronic hepatitis C virus (HCV) infection. In 15 patients who received interferon (IFN)-alpha therapy, serum levels of immunoglobulin classes and IgG subclasses were measured during treatment and after it was discontinued. In spite of important individual variations, mean IgG, IgG1, IgA and IgM levels decreased during therapy and tended to return to pre-treatment levels afterwards, with no detectable correlation with clinical and biological parameters. These results suggest an effect of IFN-alpha on in vivo immunoglobulin production, in HCV carriers.

MeSH terms

Adult
Aged
Aged, 80 and over
Alanine Transaminase / blood
Biomarkers
Female
Follow-Up Studies
Genotype
Hepacivirus / genetics
Hepatitis C / blood
Hepatitis C / immunology*
Hepatitis C / therapy
Hepatitis C / virology
Hepatitis, Chronic / blood
Hepatitis, Chronic / immunology*
Hepatitis, Chronic / therapy
Hepatitis, Chronic / virology
Humans
Immunoglobulin A / blood
Immunoglobulin G / blood*
Immunoglobulin G / classification
Immunoglobulin M / blood
Immunologic Factors / therapeutic use*
Interferon-alpha / therapeutic use*
Male
Middle Aged

Substances

Biomarkers
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Immunologic Factors
Interferon-alpha
Alanine Transaminase